INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Files An 8-K Other Events

INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Files An 8-K Other Events
Item 8.01 – Other Events

Story continues below

On January 23, 2018, the Company issued a press release announcing that it had entered into an exclusive license and distribution agreement with Lavasta Pharma FZ-LLC, a Dubai company for the distribution of its ProstaGorx® product in certain countries in the Middle East and North Africa. to the Lavasta agreement, Lavasta shall receive an upfront payment plus a transfer price on Lavasta’s minimum annual purchase requirements.

The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 — Financial Statements and Exhibits

(d) Exhibits

Exhibit Number Description

99.1 Press release issued January 23, 2018.


INNOVUS PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 ex99-1.htm PRESS RELEASE Untitled Document   Exhibit 99.1 Innovus Pharma Signs Exclusive License and Distribution Agreement with Lavasta Pharma for ProstaGorx® in Certain Middle Eastern and North African Countries   The Company to Receive an Upfront Payment plus Transfer Price on Minimum Annual Purchases Requirements   San Diego,…
To view the full exhibit click here

About INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV)

Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.

An ad to help with our costs